Business Wire

OH-PROAMPAC

20.8.2020 17:33:05 CEST | Business Wire | Press release

Share
ProAmpac Launches MAKR, a Virtual Flexible-Packaging Configurator

ProAmpac, the flexible packaging leader, today announced the launch of their online packaging design configurator branded MAKR (pronounced Make Er). MAKR allows users to remotely create custom three-dimensional package designs in both film and paper formats which can then be prototyped at the company’s Design and Sample Lab (DASL).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200820005615/en/

“Through DASL we have been ideating, designing and prototyping samples in collaboration with customers since 2014. MAKR takes our collaboration process to another level by moving ideation and design to a virtual process. Users can interact in the app with different flexible packaging formats, sizes, shapes, and art in ways that bring their ideas to life no matter where they are located. With so many of our customers working remotely during the pandemic, providing virtual, self-serve capabilities are even more relevant,” states Sal Pellingra, vice president global application & innovation.

MAKR allows users to choose almost any flexible packaging format ProAmpac produces. The user can then custom design their own package employing features such as: package dimensions, closures, handles and even the shape of the pouch. Finally, users can add graphics and submit an order for their completed package design online. ProAmpac’s DASL team will then ensure all details are correct, finalize the order, create and ship the custom prototype directly to the requester.

“This is another great example of ProAmpac’s industry-leading innovation. We’ve consistently differentiated ourselves, not only with world-class manufacturing, but also by providing packaging design services rivaling those of design firms. MAKR expands our collaborative resources and makes it easier for customers to get products from design to market in record time,” said Pellingra. “We’ve already had great feedback from our soft launch partner customers and will build out MAKR and other virtual capabilities to continue to make it easier for customers to bring new packaging ideas to a commercial reality,” Pellingra continued.

MAKR is the newest offering in a growing number of valued-added virtual offerings for ProAmpac customers under the brand name Bridge. Earlier this year ProAmpac launched Bridge Remote Trial Management (RTM), an option that allows a ProAmpac Customer Technical Service Expert to review a customer’s product trials remotely and ensure the packaging products are running efficiently.

“At ProAmpac, serving our customers is our top priority and since the onset of COVID-19 we have experienced increasing demand in virtual support requests. This led us to fast track our digital innovation platforms. MAKR and Bridge RTM are just the beginning. We have more tools and offerings coming soon to ensure our customers are getting the virtual support and service they need,” stated Adam Grose, chief commercial officer. “We feel the launch of MAKR will make it easier for our customers to do business with ProAmpac, which is ultimately the objective behind all our digital product offerings.”

To learn more about ProAmpac’s MAKR, or other offerings available through DASL, contact Nicole Cocuzzi (Nicole.Cocuzzi @Proampac.com) or go to ProAmpac.com/DASL .

Video

Demonstration of MAKR

About ProAmpac

ProAmpac is a leading global flexible packaging company with a comprehensive product offering unparalleled in the industry. We provide creative packaging solutions, industry-leading customer service and award-winning innovation to a diverse global marketplace. We are guided in our work by four core values that are the basis for our success: Integrity, Intensity, Innovation, and Involvement. Cincinnati-based ProAmpac is owned by Pritzker Private Capital along with management and co-investors. For more information, visit ProAmpac.com.

About Pritzker Private Capital

Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products, services and healthcare sectors. The firm’s differentiated, long-duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur and family owned companies. For more information, visit PPCPartners.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/ProAmpac/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye